RET and medullary thyroid gland carcinoma: Although non-MTC RET-mutated tumors have been associated with resistance to Vandetanib and Cabozantinib, RET-mutated MTC at codon V804 (gatekeeper mutation) showed indolent disease without classic MEN 2A features [107].